C.E.S. TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
23-09-2020
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
CONJUGATED ESTROGENS
可用日期:
BAUSCH HEALTH, CANADA INC.
ATC代码:
G03CA57
INN（国际名称）:
CONJUGATED ESTROGENS
剂量:
0.625MG
药物剂型:
TABLET
组成:
CONJUGATED ESTROGENS 0.625MG
给药途径:
ORAL
每包单位数:
100/1000
处方类型:
Prescription
治疗领域:
ESTROGENS
產品總結:
Active ingredient group (AIG) number: 0106442006; AHFS:
授权状态:
APPROVED
授权日期:
2020-09-23
产品特点
PRODUCT MONOGRAPH
PR
C.E.S.
Conjugated Estrogens Tablets, CSD
0.625 mg
ESTROGEN
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 23, 2020
Laval, Quebec
H7L 4A8
Control No.: 242944
_Pr_
_C.E.S._
_®_
_ Product Monograph Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................24
DETAIL
阅读完整的文件
